Pharmacokinetics and pharmacodynamics of famotidine in infants.

Abstract:

:The pharmacokinetics and pharmacodynamics of intravenous famotidine were evaluated in 10 infants ranging from 5 to 19 days of age who had a therapeutic indication for the prophylactic treatment of stress ulceration. After a 0.5-mg/kg infusion of famotidine, timed serum (n = 6), urine (24-hour collection), and repeated measurements of gastric pH were obtained. The mean +/- standard deviation maximum plasma concentration (Cmax) was 640.66 +/- 250.66 ng/mL, the elimination half-life (t1/2 beta) was 10.51 +/- 5.43 hours, and the apparent volume of distribution at steady state (Vdss) was 0.82 +/- 0.29 L/kg. Plasma clearance (Cl) and renal clearance (ClR) were 0.132 +/- 0.061 L/hr/kg and 0.093 +/- 0.056 L/hr/kg, respectively. No significant correlations were found between t1/2 beta, Vdss, Cl, and ClR and age. Six of the nine infants who had intragastric pH monitoring maintained a gastric pH > 4 until the final 24-hour sampling point. In this study, the t1/2 beta of famotidine was prolonged and the Vdss, Cl, ClR were reduced compared with corresponding parameters in previously reported studies of children older than one year of age and adults.

journal_name

J Clin Pharmacol

authors

James LP,Marotti T,Stowe CD,Farrar HC,Taylor BJ,Kearns GL

subject

Has Abstract

pub_date

1998-12-01 00:00:00

pages

1089-95

issue

12

eissn

0091-2700

issn

1552-4604

journal_volume

38

pub_type

杂志文章
  • Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.

    abstract::The efficacy and safety of esmolol, a titratable intravenous beta-adrenergic blocking agent with a short elimination half-life (t 1/2 = 9.0 min) was evaluated in a multicenter open-label study for the treatment of supraventricular tachyarrhythmias (heart rate greater than 100 bpm). The study also investigated the feas...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1988.tb03209.x

    authors: Das G,Tschida V,Gray R,Dhurandhar R,Lester R,McGrew F,Askenazi J,Kaplan K,Emanuele M,Turlapaty P

    更新日期:1988-08-01 00:00:00

  • Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine.

    abstract::Possible effects of multiple-dose administration of atorvastatin on the pharmacokinetics of single-dose antipyrine were evaluated in this drug-drug interaction study. Twelve healthy male volunteers received three 200-mg capsules of antipyrine on days 1 and 22, and two 40-mg atorvastatin tablets in the morning on days ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1996.tb04212.x

    authors: Yang BB,Hounslow NJ,Sedman AJ,Forgue ST

    更新日期:1996-04-01 00:00:00

  • Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder.

    abstract::The anxiolytic triazolobenzodiazepine alprazolam was administered to six male patients, aged 26 to 46 years, with panic disorder or agoraphobia (with panic attacks) to assess clinical effects and steady-state pharmacokinetics following multiple dosing at three levels: 3.0 mg/d, 6.0 mg/d, and 9.0 mg/d. Multiple-dose ki...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1986.tb03526.x

    authors: Ciraulo DA,Barnhill JG,Boxenbaum HG,Greenblatt DJ,Smith RB

    更新日期:1986-04-01 00:00:00

  • Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity.

    abstract::Adverse reactions to sulfonamides occur at a higher frequency in patients infected with the human immunodeficiency virus (HIV) than noninfected patients. Some studies have suggested that patients with the slow acetylator phenotype are predisposed to these reactions, whereas other studies suggest that the slow acetylat...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/00970002042006004

    authors: O'Neil WM,MacArthur RD,Farrough MJ,Doll MA,Fretland AJ,Hein DW,Crane LR,Svensson CK

    更新日期:2002-06-01 00:00:00

  • Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.

    abstract::This was a double-blind, placebo-controlled, randomized, parallel, dose-escalation study to assess the pharmacokinetics, platelet response, safety, and tolerability of supratherapeutic doses of eltrombopag (100 mg, 150 mg, and 200 mg once daily) administered for 5 days to 33 healthy adult volunteers. Plasma eltrombopa...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/0091270010368677

    authors: Matthys G,Park JW,McGuire S,Wire MB,Bowen C,Williams D,Jenkins J,Peng B

    更新日期:2011-03-01 00:00:00

  • Safety and tolerability of single intravenous doses of T cell modulatory peptide (TCMP-80) in healthy volunteers.

    abstract::T Cell Modulatory Peptide (TCMP-80), L-lysine-L-serine, is a synthetic dipeptide structurally related to a selected amino acid sequence in human immunoglobulin G. Based on in vitro and preclinical in vivo testing, TCMP-80 has immunomodulatory properties. This report describes the first administration of TCMP-80 to man...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1990.tb03605.x

    authors: Eldon MA,Smith RA,Leese PT,Daigle AE,Katz DV,Richieri SP

    更新日期:1990-04-01 00:00:00

  • "Cocktail" approaches and strategies in drug development: valuable tool or flawed science?

    abstract::There is an increasing interest in the simultaneous administration of several probe substrates to characterize the activity of multiple drug-metabolizing enzymes, the so-called "cocktail" approach. However, this method remains controversial and is being investigated more extensively. No general consensus has emerged o...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1177/0091270003261333

    authors: Zhou H,Tong Z,McLeod JF

    更新日期:2004-02-01 00:00:00

  • Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.

    abstract::The primary objective of this study was to identify intravenous regimens of tipifarnib that would mimic the systemic exposure obtained after the current twice-daily oral administration of tipifarnib. After determination of an intravenous dose that 6 subjects with advanced cancer could tolerate, another 26 subjects wer...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270006291034

    authors: Zhang S,Zannikos P,Awada A,Piccart-Gebhart M,Dirix LY,Fumoleau P,Verhaeghe T,Francois M,De Porre P

    更新日期:2006-10-01 00:00:00

  • Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.

    abstract::Steady state pharmacokinetics, absolute bioavailability, and dose proportionality of cefepime were evaluated in healthy male subjects after single (250, 500, 1000, or 2000 mg) and multiple (1000 mg every 12 hours for 10 days) intramuscular injections. Safety and tolerance were also monitored. High performance liquid c...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1990.tb03569.x

    authors: Barbhaiya RH,Knupp CA,Tenney J,Martin RR,Weidler DJ,Pittman KA

    更新日期:1990-10-01 00:00:00

  • First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.

    abstract::DS-1040, a low-molecular-weight imidazole derivative, inhibits the enzymatic activity of thrombin-activatable fibrinolysis inhibitor (TAFIa), enhancing endogenous tissue plasminogen activator-triggered fibrinolysis. This first-in-human, randomized, placebo-controlled, phase 1 study evaluated the safety, pharmacokineti...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/jcph.1474

    authors: Zhou J,Limsakun T,Yin O,Warren V,Zamora C,Atiee G,Kochan J,Pav J,Kobayashi F,Vashi V,Dishy V

    更新日期:2019-12-01 00:00:00

  • Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia.

    abstract::Lormetazepam, an investigational hypnotic, was evaluated for efficacy and withdrawal phenomena in doses of 0.5, 1.0, 1.5, and 2.0 mg in four separate sleep laboratory protocols, each including four placebo baseline nights, seven drug nights, and three placebo withdrawal nights. A moderate degree of efficacy was shown ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1982.tb02645.x

    authors: Kales A,Bixler EO,Soldatos CR,Mitsky DJ,Kales JD

    更新日期:1982-11-01 00:00:00

  • Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans.

    abstract::Pharmacokinetic studies of i.v. and oral racemic verapamil and 14C-erythromycin breath tests (ERBT) were performed in 84 healthy men (n = 42) and women (n = 42). Verapamil was measured by HPLC, concentration versus time data were analyzed by noncompartmental models, protein binding was measured by equilibrium dialysis...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/00912700022008883

    authors: Krecic-Shepard ME,Barnas CR,Slimko J,Jones MP,Schwartz JB

    更新日期:2000-03-01 00:00:00

  • Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

    abstract::Sleep disturbances and decrements of daytime performance have been attributed to HMG-CoA reductase inhibitors. As a rule, lipophilic compounds more readily cross the blood-brain barrier and are more likely to affect central nervous system function. The authors compared the effects of lovastatin (40 mg), a lipophilic c...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1994.tb01971.x

    authors: Kostis JB,Rosen RC,Wilson AC

    更新日期:1994-10-01 00:00:00

  • Application of Individualized PBPK Modeling of Rate Data (iPBPK-R) to Evaluate the Effect of Hemodialysis On Nonrenal Clearance Pathways.

    abstract::The aim of this study was to apply individualized, physiologically-based pharmacokinetic (iPBPK-R) modeling of 14 CO2 production rates measured by the erythromycin breath test (ERMBT) to characterize the effect of hemodialysis on the function of nonrenal clearance pathways in patients with end-stage renal disease (ESR...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1818

    authors: Franchetti Y,Nolin TD

    更新日期:2021-01-18 00:00:00

  • Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis.

    abstract::A series of clinical pharmacology studies was performed to screen for possible pharmacokinetic/dynamic contributions to drug interactions reported in rheumatoid arthritis patients receiving cyclosporine and nonsteroidal antiinflammatory drugs (NSAIDs). No clinically relevant pharmacokinetic changes in any of the drugs...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1997.tb04311.x

    authors: Kovarik JM,Mueller EA,Gerbeau C,Tarral A,Francheteau P,Guerret M

    更新日期:1997-04-01 00:00:00

  • Absence of effect of telbivudine on cardiac repolarization: results of a thorough QT/QTc study in healthy participants.

    abstract::The effect of telbivudine on cardiac repolarization was evaluated in healthy participants at clinical and supratherapeutic doses. Sixty-two participants were enrolled, stratified by sex, and randomized according to a crossover design among 4 treatment sequences: placebo, a single moxifloxacin 400-mg dose as positive c...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270009337943

    authors: Poordad F,Zeldin G,Harris SI,Ke J,Xu L,Mayers D,Zhou XJ

    更新日期:2009-12-01 00:00:00

  • MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.

    abstract::The most commonly used Parkinson's disease (PD) treatment is the replacement of dopamine by its levodopa precursor (l-dopa). Monoamine oxidase-B (MAO-B) and catechol-o-methyl transferase (COMT) are enzymes involved in the metabolism and regulation of dopamine availability. In our study we investigated the possible rel...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1096

    authors: Sampaio TF,Dos Santos EUD,de Lima GDC,Dos Anjos RSG,da Silva RC,Asano AGC,Asano NMJ,Crovella S,de Souza PRE

    更新日期:2018-07-01 00:00:00

  • Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers.

    abstract::The safety and pharmacokinetics of single and multiple administrations of cefpirome (HR810), a new cephalosporin antibiotic agent with a broad antibacterial spectrum, were studied in healthy male volunteers. The single administration protocols included a 3-minute intravenous injection of 0.5 g or 1 g, and a 1-hour int...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1992.tb03834.x

    authors: Nakayama I,Akieda Y,Yamaji E,Nitta Y,Ohishi M,Katagiri K,Imamura N,Takase K

    更新日期:1992-03-01 00:00:00

  • An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients.

    abstract::The pharmacokinetics and pharmacodynamics of verapamil were investigated in six chronic hemodialysis patients. A single oral 120-mg dose was administered both on a non-hemodialysis day and a hemodialysis day separated by greater than or equal to 7 days. Blood pressure and PR interval were measured simultaneously with ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1988.tb03224.x

    authors: Hanyok JJ,Chow MS,Kluger J,Izard MW

    更新日期:1988-09-01 00:00:00

  • Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.

    abstract::Aprepitant or its prodrug fosaprepitant, in combination with a corticosteroid and a 5-HT(3) receptor antagonist, are used to prevent chemotherapy-induced nausea and vomiting. This study evaluated the effect of fosaprepitant 150 mg on CYP3A4 metabolism. Fosaprepitant 150 mg has been submitted to regulatory agencies for...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270010387792

    authors: Marbury TC,Ngo PL,Shadle CR,Jin B,Panebianco D,Caro L,Valentine J,Murphy G

    更新日期:2011-12-01 00:00:00

  • Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation.

    abstract::Inhibition of ex vivo arachidonic acid (AA)-induced aggregation is a biomarker for the isotype selectivity of cyclooxygenase (COX) inhibitors since platelets express COX-1 but not COX-2. At low concentrations, there is broad inter- and intrasubject variability in AA-induced aggregation of platelets ex vivo. This study...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270003257216

    authors: Burke J,Kraft WK,Greenberg HE,Gleave M,Pitari GM,VanBuren S,Wagner JA,Waldman SA

    更新日期:2003-09-01 00:00:00

  • A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.

    abstract::The pharmacokinetics (PK) and safety of single-dose buparlisib (30 mg) were assessed in subjects with mild to severe hepatic impairment (n = 6 each) relative to healthy controls (n = 13). Blood samples were collected until 336 hours postdose and evaluated by liquid chromatography tandem mass spectrometry. PK parameter...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.590

    authors: Csonka D,Hazell K,Waldron E,Lorenzo S,Duval V,Trandafir L,Kobalava ZD

    更新日期:2016-03-01 00:00:00

  • A double-blind comparison of orally administered ciramadol and codeine for relief of postoperative pain.

    abstract::Ciramadol, a new analgesic with mixed narcotic agonist-antagonist actions, was compared with codeine and placebo in a double-blind study in 343 patients with postoperative pain. The patients received a single oral dose of either 30 or 60 mg of ciramadol, 60 mg of codeine, or placebo. As indicated by three efficacy mea...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1985.tb02882.x

    authors: Graf DF,Pandit SK,Kothary SP,Freeland GR

    更新日期:1985-11-01 00:00:00

  • The role of TNFalpha in ulcerative colitis.

    abstract::Standard of care for ulcerative colitis involves long-term pharmacotherapy or colectomy. Approximately 20% to 30% of patients eventually require a colectomy because patients either do not respond or cannot tolerate the currently available pharmacotherapies. Advances in our knowledge of the pathophysiology of ulcerativ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1177/0091270007301623

    authors: Sands BE,Kaplan GG

    更新日期:2007-08-01 00:00:00

  • Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women.

    abstract::Dienogest offers pharmacological advantages for the effective treatment of endometriosis and for use in contraception and hormone replacement therapy. This pharmacodynamic study investigated the ovulation-inhibiting effects of dienogest monotherapy in healthy women. Dienogest was administered at 0.5, 1, 2, or 3 mg dai...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270011423664

    authors: Klipping C,Duijkers I,Remmers A,Faustmann T,Zurth C,Klein S,Schuett B

    更新日期:2012-11-01 00:00:00

  • Effect of Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of the Iminosugar Sinbaglustat.

    abstract::Sinbaglustat (ACT-519276), a brain-penetrating inhibitor of glucosylceramide synthase and nonlysosomal glucosylceramidase, is developed as a new therapy for lysosomal storage disorders. In the first-in-human study, sinbaglustat was primarily excreted unchanged in urine. This study was conducted to evaluate the effect ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1808

    authors: Melchior M,Dingemanse J,Alatrach A,Feldkamp T,Sidharta PN,Géhin M

    更新日期:2020-12-23 00:00:00

  • Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.

    abstract::Neutropenia is the most commonly reported hematologic toxicity following treatment with palbociclib, a cyclin-dependent kinase 4/6 inhibitor approved for metastatic breast cancer. Using data from 185 advanced cancer patients receiving palbociclib in 3 clinical trials, a pharmacokinetic-pharmacodynamic model was develo...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/jcph.902

    authors: Sun W,O'Dwyer PJ,Finn RS,Ruiz-Garcia A,Shapiro GI,Schwartz GK,DeMichele A,Wang D

    更新日期:2017-09-01 00:00:00

  • Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

    abstract::Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ATR-107, a fully human monoclonal anti-IL-21 receptor (IL-21R) antibody, administered as ascending single doses, subcutaneously or intravenously, was evaluated in a placebo-controlled, double-blind trial in healthy subjects. The dose levels were...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/jcph.158

    authors: Hua F,Comer GM,Stockert L,Jin B,Nowak J,Pleasic-Williams S,Wunderlich D,Cheng J,Beebe JS

    更新日期:2014-01-01 00:00:00

  • The pharmacokinetics and pharmacodynamics of minaxolone.

    abstract::Plasma concentrations of minaxolone were measured in 15 female patients during and for up to 3 hours after a minaxolone and nitrous oxide anesthetic. Nine patients received a single dose and six patients two or three doses of minaxolone. Plasma minaxolone decay can be described by two-compartment kinetics. Distributio...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1982.tb02681.x

    authors: Dunn GL,Morison DH,McChesney J,Pine W,Kumana CR,Gupta RN

    更新日期:1982-07-01 00:00:00

  • Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.

    abstract::Selection of the first dose for neonates in clinical trials is very challenging. The objective of this analysis was to assess if a population pharmacokinetic (PK) model developed with data from infants to adults is predictive of neonatal clearance and to evaluate what age range of prior PK data is needed for informati...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.524

    authors: Wang J,Edginton AN,Avant D,Burckart GJ

    更新日期:2015-10-01 00:00:00